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ABSTRACT  There is controversy over the degree of inflammatory bowel disease activity after 
transplant. We herein report the case of a patient who presented with an ileal perforation after 
infliximab treatment for Crohn's disease in a heart transplant patient under immunosuppressive 
therapy. A 30-year-old male with an 11-year history of Crohn's disease underwent a heart 
transplant. Five years after the transplant, he presented symptoms consistent with intermittent 
small bowel obstruction related to Crohn's disease and received infliximab therapy. Three 
months after the induction of the therapy, he presented with sudden intense abdominal pain and 
an emergent laparotomy revealed fecal panperitonitis due to a perforation of the distal ileum. 
The long-term usage of immunosuppressive agents, especially steroids, before the induction of 
infliximab may have an unfavorable effect on Crohn's disease treatment.
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INTRODUCTION
   The safety and efficacy of infliximab, a 
chimeric monoclonal immunoglobulin antibody 
to tumor necrosis factor, has been established in 
a number of controlled trials for the treatment of 
moderate to severe active and fistulizing Crohn's 
disease (CD)１,２）. However, CD is an idiopathic 
disorder which most likely has an autoimmune 
etiology３）. We herein report the case of a heart 
transplant patient under immunosuppressive therapy 
who presented with an ileal perforation after 
infliximab treatment for CD.
CASE REPORT
   A 30-year-old Japanese male with an 11-year 
history of CD underwent a heart transplant for 
dilated cardiomyopathy in the USA in 1997. After 
the transplant, initially he was maintained on an 
immunosuppressive regimen that included cyclosporine 
A (150-175 mg/day) and mycophenolate mofetil 
(1,500 mg/day). Two years later, prednisolone (2 
mg/day) was added due to an allograft rejection. 
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The patient's post-transplant course was uneventful 
regarding his heart. Before the transplant and five 
years afterwards, he presented no symptoms related 
to CD and he had received no treatment for it. In 
2002, he underwent an operation for an anal fistula 
and a peri-anal abscess as a result of CD. At that 
time, he presented with symptoms consistent with 
intermittent small bowel obstruction related to 
CD and he was therefore hospitalized to receive 
conservative therapy. In January 2003, a barium 
bowel series and enteroscopy demonstrated severe 
stenosis (Fig. 1), in addition to longitudinal deep 
ulcerations in the distal small intestine. Beginning in 
February 2003, he received infliximab (5 mg/kg of 
body weight) intravenously three times at weeks 0, 
2, and 6 (Fig. 2). In the middle of March, his bowel 
symptoms had improved significantly and he could 
eat normally. A follow-up barium small bowel series 
and enteroscopy demonstrated an improvement 
in findings. The severe stenosis and longitudinal 
deep ulcerations had, respectively, become mild 
and superficial. During the infliximab treatment, 
he continued to receive the immunosuppressive 
regimen for the heart transplant. He was discharged 
from the hospital on March 21. On May 7, he 
presented with sudden intense abdominal pain and 
was referred to our hospital (Fig. 3). An emergent 
laparotomy revealed fecal panperitonitis due to a 
perforation of the distal ileum. The inflammatory 
segment including the perforated segment of the 
ileum was removed and an ileal stoma was made. 
The specimen showed the perforation to be located 
at the bottom of a longitudinal ulceration (Fig. 4). 
The postoperative course was uneventful. 
DISCUSSION
   There are two contradictions in this case. Based on 
the theory that an inflammatory bowel disease (IBD) 
such as CD is an autoimmune disease, a flare-up of 
CD in a patient under immunosuppressive therapy 
is the first contradiction. There is controversy over 
Fig. 1. A barium small bowel study before infliximab 
treatment demonstrates severe  stenosis of the ileum (arrows).
Fig. 2. The clinical course showed that there were no 
symptoms related to Crohn's disease for five years after the 
induction of immunosuppressive agents, and ileal perforation 
occurred three months after the start of infliximab therapy.
Fig. 3. Chest X-ray on emergent arrival is uneventful 
regarding his heart.
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the degree of IBD activity after transplant. There 
have been reports of no difference in IBD activity 
and improvement in IBD symptoms４，５）. Riley et 
al.２） reported 14 patients (0.2%) who developed 
IBD after a transplant despite immunosuppression, 
and the average time to IBD diagnosis was four 
years. In this case, a flare-up of CD occurred five 
years after the transplant. Cyclosporine, one of the 
immunosuppressive agents, might therefore not be 
an effective agent for remission in CD５）.
   The subsequent intestinal perforation after 
the  adminis t ra t ion  of  in f l ix imab,  desp i te  
immunosuppression, is a second contradiction. 
Intestinal perforation is a very rare adverse event 
of infliximab１）. The response to infliximab tends 
to improve when concomitant immunosuppressive 
therapy is given６）. Immunosuppressive agents 
should therefore be added to infliximab treatment 
to avoid an infusion reaction and/or the formation 
of antibodies to infliximab. Interestingly, the 
perforation developed after an improvement in his 
condition following infliximab administration, and 
at first the infliximab seemed to be effective for this 
case. The specific issue in the present case is that 
the patient had been receiving long-term steroid 
therapy. The long-term usage of steroids might 
therefore suppress the inflammatory changes, such 
as thickness and fibrosis, in ulcers related to CD, 
thereby resulting in fragility of the inflammatory 
lesion. The long-term usage of immunosuppressive 
agents, especially steroids, before the induction of 
infliximab may therefore have an unfavorable effect 
on CD treatment. 
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Fig. 4. The perforation is located at the bottom of the ulcer. 
The probe is inserted into the perforated part.
